ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 64 filers reported holding ALPINE IMMUNE SCIENCES INC in Q4 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $181,391 | +15.5% | 15,842 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $157,068 | +78.2% | 15,279 | +33.8% | 0.00% | 0.0% |
| Q1 2023 | $88,147 | +12.0% | 11,418 | +6.6% | 0.00% | 0.0% |
| Q4 2022 | $78,719 | +48.5% | 10,710 | +44.4% | 0.00% | – |
| Q3 2022 | $53,000 | -14.5% | 7,415 | +1.4% | 0.00% | – |
| Q2 2022 | $62,000 | +19.2% | 7,310 | +26.8% | 0.00% | – |
| Q1 2022 | $52,000 | -38.8% | 5,767 | -6.6% | 0.00% | – |
| Q4 2021 | $85,000 | +25.0% | 6,173 | -2.9% | 0.00% | – |
| Q3 2021 | $68,000 | +15.3% | 6,358 | -2.3% | 0.00% | – |
| Q2 2021 | $59,000 | – | 6,509 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |